The selective inhibitor of BCL2, ABT199 (venetoclax), has been approved for the treatment of chronic lymphocytic leukemia (CLL) and acute myeloid leukemia (AML) [9, 10], highlighting the potential of this targeted treatment therapy. The gene discussed is BCL2; the disease is B-cell chronic lymphocytic leukemia.